JP6021187B2 - 自閉症の代謝バイオマーカー - Google Patents

自閉症の代謝バイオマーカー Download PDF

Info

Publication number
JP6021187B2
JP6021187B2 JP2013508294A JP2013508294A JP6021187B2 JP 6021187 B2 JP6021187 B2 JP 6021187B2 JP 2013508294 A JP2013508294 A JP 2013508294A JP 2013508294 A JP2013508294 A JP 2013508294A JP 6021187 B2 JP6021187 B2 JP 6021187B2
Authority
JP
Japan
Prior art keywords
autism
metabolites
brain
autistic
cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013508294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525801A5 (enExample
JP2013525801A (ja
Inventor
ガブリエラ ゲブリン セザー，
ガブリエラ ゲブリン セザー，
アラン エム． スミス，
アラン エム． スミス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of JP2013525801A publication Critical patent/JP2013525801A/ja
Publication of JP2013525801A5 publication Critical patent/JP2013525801A5/ja
Application granted granted Critical
Publication of JP6021187B2 publication Critical patent/JP6021187B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
JP2013508294A 2010-04-29 2011-04-29 自閉症の代謝バイオマーカー Expired - Fee Related JP6021187B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32951510P 2010-04-29 2010-04-29
US61/329,515 2010-04-29
PCT/US2011/034654 WO2011139914A1 (en) 2010-04-29 2011-04-29 Metabolic biomarkers of autism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015189529A Division JP2015231392A (ja) 2010-04-29 2015-09-28 自閉症の代謝バイオマーカー

Publications (3)

Publication Number Publication Date
JP2013525801A JP2013525801A (ja) 2013-06-20
JP2013525801A5 JP2013525801A5 (enExample) 2014-05-22
JP6021187B2 true JP6021187B2 (ja) 2016-11-09

Family

ID=44533446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013508294A Expired - Fee Related JP6021187B2 (ja) 2010-04-29 2011-04-29 自閉症の代謝バイオマーカー
JP2015189529A Pending JP2015231392A (ja) 2010-04-29 2015-09-28 自閉症の代謝バイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015189529A Pending JP2015231392A (ja) 2010-04-29 2015-09-28 自閉症の代謝バイオマーカー

Country Status (6)

Country Link
US (2) US9547013B2 (enExample)
EP (1) EP2564194B1 (enExample)
JP (2) JP6021187B2 (enExample)
AU (2) AU2011248464B2 (enExample)
CA (1) CA2797787C (enExample)
WO (1) WO2011139914A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101322695B1 (ko) * 2010-08-25 2013-10-25 주식회사 엘지화학 케이블형 이차전지
LT3072524T (lt) 2010-10-07 2018-03-26 California Institute Of Technology Probiotikai, skirti autizmo gydymui
EP2890808A4 (en) * 2012-08-29 2016-09-28 California Inst Of Techn DIAGNOSIS AND TREATMENT OF AUTISTICAL DISEASES
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US20160209428A1 (en) * 2013-08-21 2016-07-21 The Regents Of The University Of California Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system
AU2015243857A1 (en) * 2014-04-08 2016-10-20 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
EP3212207A4 (en) 2014-10-30 2018-06-13 California Institute of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
JP6800846B2 (ja) 2014-10-30 2020-12-16 カリフォルニア インスティチュート オブ テクノロジー 神経発達症群における行動の改善のための細菌含有組成物、及び細菌を使用することを含む、神経発達症群における行動の改善のための方法
EP3265820B1 (en) 2015-03-06 2023-12-13 Micromass UK Limited Spectrometric analysis of microbes
CA2978042A1 (en) 2015-03-06 2016-09-15 Micromass Uk Limited Tissue analysis by mass spectrometry or ion mobility spectrometry
CN112557491B (zh) * 2015-03-06 2024-06-28 英国质谱公司 光谱分析
GB2556436B (en) 2015-03-06 2022-01-26 Micromass Ltd Cell population analysis
JP6421742B2 (ja) 2015-11-27 2018-11-14 株式会社デンソー 車両制御装置
WO2017178833A1 (en) 2016-04-14 2017-10-19 Micromass Uk Limited Spectrometric analysis of plants
CN109642904A (zh) 2016-05-23 2019-04-16 加州理工学院 调节肠微生物群来治疗神经退行性病症
CN107064340A (zh) * 2017-03-13 2017-08-18 瀚盟测试科技（天津）有限公司 一种检测茶叶中gaba含量的方法
WO2018213204A1 (en) 2017-05-15 2018-11-22 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
GB201802116D0 (en) 2018-02-09 2018-03-28 Univ Warwick Methods for diagnosing an autistic spectrum disorder
CN109030665A (zh) * 2018-10-08 2018-12-18 黑龙江大学 亲水性液相色谱串联质谱法测定红甜菜中甜菜碱含量的检测方法
KR102550459B1 (ko) 2018-11-06 2023-07-03 스탈리클라 에스에이 특발성 자폐 스펙트럼 장애 환자의 하위 집단, asd 표현형 1의 진단을 위한 대사 프로파일링
EP4012414A1 (en) 2020-12-11 2022-06-15 Stalicla S.A. Diagnosis of autism spectrum disorder phenotype 1
CN113960200B (zh) * 2021-10-19 2023-06-20 首都医科大学附属北京儿童医院 代谢标志物在诊断儿童adhd合并抽动障碍中的应用
CN114705775B (zh) * 2022-03-31 2023-09-12 广东省结核病控制中心 一种肺结核评价的血清代谢标志物及其应用
CN115326953A (zh) * 2022-08-02 2022-11-11 云谱康(大连)生物科技有限公司 一种代谢物组合及应用和检测试剂盒与使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
CA2273683A1 (en) * 1998-06-15 1999-12-15 Ortho-Clinical Diagnostics, Inc. Diagnostic markers for human disorders
CA2511501A1 (en) 2002-12-24 2004-07-15 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
GB0504096D0 (en) 2005-02-28 2005-04-06 Tipogen As Method
WO2006121952A2 (en) * 2005-05-05 2006-11-16 The Regents Of The University Of California Diagnostic biomarkers for neurodevelopmental disorders
EP2013619B1 (en) * 2006-04-10 2017-10-11 Wisconsin Alumni Research Foundation Methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals
EP2052255A2 (en) * 2006-08-18 2009-04-29 Huntington Medical Research Institutes Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
EP2183589A4 (en) * 2007-07-26 2011-03-16 Phenomenome Discoveries Inc METHODS FOR THE DIAGNOSIS, RISK ASSESSMENT AND MONITORING OF AUTISM SPECTRUM DISORDERS
US20100248235A1 (en) * 2007-10-04 2010-09-30 Scherer Stephen W Biomarkers for autism spectrum disorders
EP2279417B1 (en) * 2008-05-28 2016-07-20 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof

Also Published As

Publication number Publication date
JP2015231392A (ja) 2015-12-24
CA2797787C (en) 2019-07-09
CA2797787A1 (en) 2011-11-10
EP2564194B1 (en) 2019-07-10
AU2011248464B2 (en) 2016-08-11
JP2013525801A (ja) 2013-06-20
US20120190055A1 (en) 2012-07-26
AU2011248464A1 (en) 2012-11-22
US9547013B2 (en) 2017-01-17
EP2564194A1 (en) 2013-03-06
AU2016204969A1 (en) 2016-08-04
US20170192019A1 (en) 2017-07-06
WO2011139914A1 (en) 2011-11-10
AU2016204969B2 (en) 2018-05-17
US10330688B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
JP6021187B2 (ja) 自閉症の代謝バイオマーカー
JP6763770B2 (ja) 自閉症スペクトラム障害のバイオマーカー
CN105209909B (zh) 与肾功能相关的生物标记及其使用方法
US20210325409A1 (en) Biomarkers and uses thereof for diagnosing the silent phase of alzheimer's disease
JP6873490B2 (ja) 糖尿病関連バイオマーカーおよび糖尿病関連状態の処置
Cheng et al. Metabolic disturbances in plasma as biomarkers for Huntington's disease
German et al. Serum biomarkers for Alzheimer's disease: proteomic discovery
US20140165700A1 (en) Method of diagnosing on increased risk of alzheimer's disease
Cui et al. Salivary metabolomics reveals that metabolic alterations precede the onset of schizophrenia
CN104515860A (zh) 生物标记用于制备心脏衰竭诊断组合物的用途及诊断装置
CN107667293A (zh) 用于阿茲海默氏病的诊断工具
US20150212098A1 (en) Diagnostic assay for alzheimer's disease
LeWitt et al. Diagnostic metabolomic profiling of Parkinson's disease biospecimens
JP2019168319A (ja) 小児がん検査用尿中代謝物マーカー
CN116678974A (zh) 一种阿尔茨海默症血浆代谢标志物的筛选方法、血浆代谢标志物及应用
CN109946411A (zh) 用于胸椎黄韧带骨化诊断的生物标记物及其筛选方法
CN111693624A (zh) 一种与儿童多发性抽动症诊断相关的血浆代谢标志物及其应用
CN109946467B (zh) 一种用于胸椎黄韧带骨化诊断的生物标记物
Berezhnoy et al. Application of IVDr NMR spectroscopy to stratify Parkinson’s disease with absolute quantitation of blood serum metabolites and lipoproteins
CN115754260A (zh) 一种阿尔兹海默症粪便代谢标志物及其筛选方法和应用
WO2015183917A2 (en) Metabolic biomarkers for memory loss
Lan et al. An integration of neuroimaging and serum proteomics analysis suggests immune and inflammation are associated with white matter microstructure changes in cerebral small vessel disease with depressive symptoms
CN119846187B (zh) 用于诊断阿尔茨海默病的头发代谢标志物组合及其应用
WO2025263405A1 (ja) 筋萎縮性側索硬化症における判定、疾患修飾薬治療効果予測および判定、モニタリング、並びに層別化のためのバイオマーカーおよび方法
WO2024189238A1 (en) Biomarkers discriminating phenotypes of x-adrenoleukodystrophy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150626

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150724

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160928

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160929

R150 Certificate of patent or registration of utility model

Ref document number: 6021187

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees